Sugi Predict

Sugi Predict / Compounds / SCHEMBL282595

SCHEMBL282595

SCHEMBL282595

CCOC(=O)c1c(C)cccc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.58
▸ CA1 P00915 2/20 0.58
▸ CA2 P00918 2/20 0.58
▸ CA7 P43166 2/20 0.58
▸ CA9 Q16790 2/20 0.58
▸ CA14 Q9ULX7 2/20 0.58
▸ TAS1R3 Q7RTX0 1/20 0.55
▸ TAS1R1 Q7RTX1 1/20 0.55
▸ TAS1R2 Q8TE23 1/20 0.55
▸ TSHR P16473 2/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.49
▸ ATM Q13315 1/20 0.48
▸ HSD17B2 P37059 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10455857 0.91 CA12 (0.63) CA12CA1CA2CA7CA9
SCHEMBL17502724 0.86 TSHR (0.51) CA12CA1CA2CA7CA9
SCHEMBL570471 0.85 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL4273334 0.84 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL30320392 0.84 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL7213192 0.84 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL16041589 0.83 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL7560964 0.83 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL30822598 0.83 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL4943629 0.83 CA12 (0.54) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171464-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-05-29 — — US disclosed
US-12275745-B2 Therapeutic compounds and methods of use GENENTECH, INC. (US) 2025-04-15 — — US disclosed
CN-119462608-A Fused ring CYP11A1 inhibitors 轩竹生物科技股份有限公司 2025-02-18 — — CN disclosed
EP-4436969-A2 BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-10-02 — — EP disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 — — EP disclosed
CN-118451077-A Bicyclic therapeutic compounds and methods for treatment of cancer 基因泰克公司 2024-08-06 — — CN disclosed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 — — CN disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 — — US disclosed
WO-2001019830-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2001-03-22 — — WO disclosed
WO-2001017516-A2 METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 NOVO NORDISK A/S (DK) 2001-03-15 — — WO disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 — — EP disclosed
US-6001883-A SUBSTITUTED BENZOPHENONES OF GIVEN FORMULA, SUCH AS 6,6'-DIMETHYL-2,2',3',4'-TETRAMETHOXY-5-TRIFLUOROMETHYL-BENZOPHENONE; HIGHLY SYSTEMIC FUNGICIDES; CONTROLLING FUNGAL DISEASE SUCH AS POWDERY MILDEW IN PLANTS AMERICAN CYANAMID COMPANY (US) 1999-12-14 — — US disclosed
US-5945567-A Fungicidal 2-methoxybenzophenones AMERICAN CYANAMID COMPANY (US) 1999-08-31 — — US disclosed
US-5922905-A INTERMEDIATES FOR FUNGICIDES AMERICAN CYANAMID COMPANY (US) 1999-07-13 — — US disclosed
CN-1217317-A Fungicidal 2-methoxybenzophenones AMERICAN CYANAMID CO (US) 1999-05-26 — — CN disclosed
EP-0897904-A1 Fungicidal 2-methoxybenzophenones American Cyanamid Company (US) 1999-02-24 — — EP disclosed
WO-1993014086-A1 SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1993-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171464-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 CA12 1168/4885CA1 3324/4885CA2 2946/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS CA12 4073/4885CA1 3363/4885CA2 4095/4885
US-12275745-B2 Therapeutic compounds and methods of use VHL, TP53, MCL1 CA12 1168/4885CA1 3324/4885CA2 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.